Denver Health Medical Center
- Type
- Teaching hospital
- Where
- Denver, CO
- Medicare CCN
- 060011
- Received
- $9,347,731 in 237 records, 2020 ($5,191,914 general, $4,155,816 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 151 | $5,191,914 |
| 2020 | Research payment | 86 | $4,155,816 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 90 | $4,196,563 |
| Research payment | 86 | $4,155,816 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 45 | $853,422 |
| Grant | 4 | $96,179 |
| Education | 5 | $34,037 |
| Gift | 4 | $10,902 |
| Charitable Contribution | 1 | $466 |
| Travel and Lodging | 2 | $342 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Gilead Sciences, Inc. | $39,733 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-31 | Haemonetics Corporation | $27,264 | Education | In-kind items and services | TEG Device, Devices | 2020 | |
| 2020-12-23 | Genentech, Inc. | $245,442 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA | 2020 |
| 2020-12-23 | Purdue Pharma L.P. | $208,333 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-12-23 | Purdue Pharma L.P. | $8,545 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-12-23 | Gilead Sciences, Inc. | $3,826 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2020 | |
| 2020-12-23 | Zimmer Biomet Holdings, Inc. | $2,500 | Research payment | Cash or cash equivalent | Continuum Device, Hips | CMU2010-02H, Continuum MoP PMCF | 2020 |
| 2020-12-22 | Indivior Inc. | $46,408 | Research payment | Cash or cash equivalent | Annual RADARS System Subscription/Lit Review | 2020 | |
| 2020-12-21 | Janssen Scientific Affairs, LLC | $151,200 | Research payment | Cash or cash equivalent | 2020 | ||
| 2020-12-21 | Gen-Probe, Inc. | $10,429 | Research payment | Cash or cash equivalent | Aptima Device, Diagnostics | Year 1: Surveillance for Mycoplasma genitalium in US Sexually Transmitted Disease (STD) Clinics | 2020 |
| 2020-12-18 | Sterilmed, Inc. | $197 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-12-16 | Exelixis Inc. | $52,817 | Consulting Fee | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-12-16 | Hikma Pharmaceuticals USA | $52,795 | Consulting Fee | Cash or cash equivalent | Buprenorphine & Naloxone Drug, Endocrinology | 2020 | |
| 2020-12-16 | Exelixis Inc. | $2,420 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-12-14 | UPJOHN US 1 LLC | $25,000 | Research payment | Cash or cash equivalent | LYRICA Drug, NEUROSCIENCE;PAIN | MANUSCRIPT PREPARED ON THE TOPIC PREGABALIN | 2020 |
| 2020-12-03 | SANOFI PASTEUR INC. | $37,835 | Research payment | Cash or cash equivalent | STA00011 Stamaril Yellow Fever | 2020 | |
| 2020-12-02 | Indivior Inc. | $46,408 | Research payment | Cash or cash equivalent | Annual RADARS System Subscription/Lit Review | 2020 | |
| 2020-12-02 | Zimmer Biomet Holdings, Inc. | $466 | Research payment | Cash or cash equivalent | Continuum Device, Hips | CMU2010-02H, Continuum MoP PMCF | 2020 |
| 2020-12-01 | Rhodes Pharmaceuticals L.P. | $16,566 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-12-01 | Rhodes Pharmaceuticals L.P. | $16,334 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-12-01 | Gen-Probe, Inc. | $2,920 | Research payment | Cash or cash equivalent | Aptima Device, Diagnostics | Year 1: Surveillance for Mycoplasma genitalium in US Sexually Transmitted Disease (STD) Clinics | 2020 |
| 2020-11-25 | Purdue Pharma L.P. | $208,333 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-11-19 | BTG International Inc. | $49,392 | Research payment | Cash or cash equivalent | CROFAB Drug, ANTI-VENOM | CROFAB | 2020 |
| 2020-11-19 | BTG International Inc. | $37,680 | Research payment | Cash or cash equivalent | CROFAB Drug, ANTI-VENOM | CROFAB | 2020 |
| 2020-11-13 | Purdue Pharma L.P. | $7,597 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-11-12 | BTG International Inc. | $44,877 | Research payment | Cash or cash equivalent | CROFAB Drug, ANTI-VENOM | CROFAB | 2020 |
| 2020-11-12 | BTG International Inc. | $36,040 | Research payment | Cash or cash equivalent | CROFAB Drug, ANTI-VENOM | CROFAB | 2020 |
| 2020-11-12 | BTG International Inc. | $34,500 | Research payment | Cash or cash equivalent | CROFAB Drug, ANTI-VENOM | CROFAB | 2020 |
| 2020-11-12 | BTG International Inc. | $27,600 | Research payment | Cash or cash equivalent | CROFAB Drug, ANTI-VENOM | CROFAB | 2020 |
| 2020-11-12 | BTG International Inc. | $21,111 | Research payment | Cash or cash equivalent | CROFAB Drug, ANTI-VENOM | CROFAB | 2020 |
| 2020-11-12 | BTG International Inc. | $21,111 | Research payment | Cash or cash equivalent | CROFAB Drug, ANTI-VENOM | CROFAB | 2020 |
| 2020-11-12 | BTG International Inc. | $19,250 | Research payment | Cash or cash equivalent | CROFAB Drug, ANTI-VENOM | CROFAB | 2020 |
| 2020-11-12 | BTG International Inc. | $9,000 | Research payment | Cash or cash equivalent | CROFAB Drug, ANTI-VENOM | CROFAB | 2020 |
| 2020-11-12 | BTG International Inc. | $6,000 | Research payment | Cash or cash equivalent | CROFAB Drug, ANTI-VENOM | CROFAB | 2020 |
| 2020-11-12 | Sterilmed, Inc. | $133 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-11-11 | Exelixis Inc. | $53,708 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-11-11 | Exelixis Inc. | $2,420 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-11-09 | UPJOHN US 1 LLC | $308,279 | Research payment | Cash or cash equivalent | RADARS WILL COLLECT AND ANALYZE REAL WORLD PREGABALIN AND GABAPENTIN AND WILL PREPARE REPORT OF THEIR ANALYSES | 2020 | |
| 2020-11-09 | UPJOHN US 1 LLC | $50,000 | Research payment | Cash or cash equivalent | RADARS WILL COLLECT AND ANALYZE REAL WORLD PREGABALIN AND GABAPENTIN AND WILL PREPARE REPORT OF THEIR ANALYSES | 2020 | |
| 2020-11-04 | Indivior Inc. | $54,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-11-04 | Indivior Inc. | $44,627 | Research payment | Cash or cash equivalent | Annual RADARS System Subscription/Lit Review | 2020 | |
| 2020-11-04 | Indivior Inc. | $244 | Travel and Lodging | Cash or cash equivalent | 2020 | ||
| 2020-11-04 | Indivior Inc. | $98 | Travel and Lodging | Cash or cash equivalent | 2020 | ||
| 2020-10-30 | Purdue Pharma L.P. | $21,187 | Consulting Fee | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2020 | |
| 2020-10-30 | Purdue Pharma L.P. | $16,170 | Consulting Fee | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2020 | |
| 2020-10-28 | Purdue Pharma L.P. | $208,333 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-10-28 | Mallinckrodt LLC | $115,732 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-10-28 | Rhodes Pharmaceuticals L.P. | $32,227 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-10-28 | Purdue Pharma L.P. | $16,747 | Consulting Fee | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2020 | |
| 2020-10-28 | Purdue Pharma L.P. | $12,750 | Consulting Fee | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2020 | |
| 2020-10-28 | Hikma Pharmaceuticals USA | $5,194 | Consulting Fee | Cash or cash equivalent | Morphine Sulfate ER tablets Drug, Psychiatry/Psychology | 2020 | |
| 2020-10-28 | Purdue Pharma L.P. | $4,976 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-10-28 | Mallinckrodt LLC | $4,256 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-10-28 | Mylan Specialty L.P. | $3,844 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-10-28 | Rhodes Pharmaceuticals L.P. | $1,185 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-10-28 | UPSHER-SMITH LABORATORIES LLC | $681 | Consulting Fee | Cash or cash equivalent | MORPHINE SULFATE EXTENDED RELEASE CAPSULES USP CII Drug, NEUROLOGY | 2020 | |
| 2020-10-28 | Hikma Pharmaceuticals USA | $191 | Consulting Fee | Cash or cash equivalent | Morphine Sulfate ER tablets Drug, Psychiatry/Psychology | 2020 | |
| 2020-10-28 | Purdue Pharma L.P. | $183 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-10-28 | Mylan Specialty L.P. | $141 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-10-21 | Gilead Sciences, Inc. | $3,626 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2020 | |
| 2020-10-16 | Roche Products Limited | $1,731 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-10-14 | Purdue Pharma L.P. | $7,850 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-10-12 | UPJOHN US 1 LLC | $50,000 | Research payment | Cash or cash equivalent | RADARS WILL COLLECT AND ANALYZE REAL WORLD PREGABALIN AND GABAPENTIN AND WILL PREPARE REPORT OF THEIR ANALYSES | 2020 | |
| 2020-10-08 | Indivior Inc. | $46,408 | Research payment | Cash or cash equivalent | Annual RADARS System Subscription/Lit Review | 2020 | |
| 2020-10-08 | Indivior Inc. | $26,000 | Research payment | Cash or cash equivalent | RADARS System DMI | 2020 | |
| 2020-10-08 | Hikma Pharmaceuticals USA | $11,323 | Consulting Fee | Cash or cash equivalent | MORPHINE SULFATE Drug, Psychiatry/Psychology | 2020 | |
| 2020-10-07 | Exelixis Inc. | $53,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-10-07 | Exelixis Inc. | $2,420 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-10-07 | Sterilmed, Inc. | $240 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-10-05 | Gen-Probe, Inc. | $5,043 | Research payment | Cash or cash equivalent | Aptima Device, Diagnostics | Year 1: Surveillance for Mycoplasma genitalium in US Sexually Transmitted Disease (STD) Clinics | 2020 |
| 2020-10-01 | Hikma Pharmaceuticals USA | $11,236 | Consulting Fee | Cash or cash equivalent | MORPHINE SULFATE Drug, Psychiatry/Psychology | 2020 | |
| 2020-09-24 | Rhodes Pharmaceuticals L.P. | $17,513 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-09-24 | Teva Pharmaceuticals USA, Inc. | $10,969 | Research payment | Cash or cash equivalent | BUPRENORPHINE Drug, Central Nervous System | BTOD REMS Program | 2020 |
| 2020-09-23 | Purdue Pharma L.P. | $208,333 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-09-23 | Dr.Reddy's Laboratories,Inc. | $43,514 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Buprenorphine and Naloxone Drug, Psychiatry/Psychology | 2020 | |
| 2020-09-23 | Purdue Pharma L.P. | $10,500 | Consulting Fee | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2020 | |
| 2020-09-23 | Gilead Sciences, Inc. | $6,180 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2020 | |
| 2020-09-16 | Genentech, Inc. | $97,581 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA | 2020 |
| 2020-09-16 | Purdue Pharma L.P. | $6,186 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-09-09 | Exelixis Inc. | $50,567 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-09-09 | Exelixis Inc. | $2,420 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-09-05 | Indivior Inc. | $46,408 | Research payment | Cash or cash equivalent | Annual RADARS System Subscription/Lit Review | 2020 | |
| 2020-09-03 | Mylan Inc. | $11,419 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Buprenorphine Hydrochloride Drug, Central Nervous System | 2020 | |
| 2020-08-28 | Purdue Pharma L.P. | $10,972 | Consulting Fee | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2020 | |
| 2020-08-27 | Teva Pharmaceuticals USA, Inc. | $10,720 | Research payment | Cash or cash equivalent | BUPRENORPHINE Drug, Central Nervous System | BTOD REMS Program | 2020 |
| 2020-08-26 | Roche Products Limited | $16,502 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-08-26 | ZOLL Circulation Inc | $944 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2020 | |
| 2020-08-21 | Purdue Pharma L.P. | $208,333 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-08-21 | Purdue Pharma L.P. | $14,630 | Consulting Fee | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2020 | |
| 2020-08-21 | Purdue Pharma L.P. | $6,352 | Consulting Fee | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2020 | |
| 2020-08-21 | Purdue Pharma L.P. | $3,562 | Consulting Fee | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2020 | |
| 2020-08-18 | Hikma Pharmaceuticals USA | $58,965 | Consulting Fee | Cash or cash equivalent | MORPHINE SULFATE Drug, Psychiatry/Psychology | 2020 | |
| 2020-08-17 | Rhodes Pharmaceuticals L.P. | $17,953 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-08-12 | Purdue Pharma L.P. | $5,978 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-08-12 | Exelixis Inc. | $2,420 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-08-10 | BONE SUPPORT AB | $1,466 | Research payment | Cash or cash equivalent | CERAMENT G Device, Bone void and fracture | A Prospective, Randomized Multicenter Controlled Trial of CERAMENT G as Part of Surgical Repair of Open Diaphyseal Tibia | 2020 |
| 2020-08-08 | Indivior Inc. | $46,408 | Research payment | Cash or cash equivalent | Annual RADARS System Subscription/Lit Review | 2020 | |
| 2020-08-05 | Sterilmed, Inc. | $191 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-08-05 | Sterilmed, Inc. | $76 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-08-04 | Genentech, Inc. | $288,712 | Research payment | Cash or cash equivalent | Activase Biological, Metabolism & Primary Care | FIBRINOLYTIC THERAPY TO TREAT ARDS IN THE SETTING OF COVID 19 INFECTION A PHASE 2A CLINICAL TRIAL | 2020 |
| 2020-08-03 | Janssen Scientific Affairs, LLC | $151,200 | Research payment | Cash or cash equivalent | 2020 | ||
| 2020-08-01 | Zimmer Biomet Holdings, Inc. | $14,885 | Grant | Cash or cash equivalent | Grants Device, General | 2020 | |
| 2020-08-01 | Medical Device Business Services, Inc. | $2,206 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-07-30 | Mylan Inc. | $10,793 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Buprenorphine Hydrochloride Drug, Central Nervous System | 2020 | |
| 2020-07-24 | Purdue Pharma L.P. | $208,333 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-07-24 | Purdue Pharma L.P. | $5,390 | Consulting Fee | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2020 | |
| 2020-07-24 | Purdue Pharma L.P. | $5,062 | Consulting Fee | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2020 | |
| 2020-07-23 | Mallinckrodt LLC | $68,496 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-07-23 | Rhodes Pharmaceuticals L.P. | $18,832 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-07-23 | Mylan Specialty L.P. | $3,259 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-07-23 | Hikma Pharmaceuticals USA | $3,035 | Consulting Fee | Cash or cash equivalent | Morphine Sulfate ER tablets Drug, Psychiatry/Psychology | 2020 | |
| 2020-07-23 | Purdue Pharma L.P. | $2,908 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-07-23 | Mallinckrodt LLC | $1,784 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-07-23 | Rhodes Pharmaceuticals L.P. | $490 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-07-23 | UPSHER-SMITH LABORATORIES LLC | $369 | Consulting Fee | Cash or cash equivalent | MORPHINE SULFATE EXTENDED RELEASE CAPSULES USP CII Drug, NEUROLOGY | 2020 | |
| 2020-07-23 | Mylan Specialty L.P. | $84 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-07-23 | Hikma Pharmaceuticals USA | $79 | Consulting Fee | Cash or cash equivalent | Oxymorphone hydrochloride ER tablet Drug, Psychiatry/Psychology | 2020 | |
| 2020-07-23 | Purdue Pharma L.P. | $75 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-07-22 | Purdue Pharma L.P. | $6,488 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-07-21 | Hikma Pharmaceuticals USA | $54,120 | Consulting Fee | Cash or cash equivalent | Buprenorphine Drug, Endocrinology | 2020 | |
| 2020-07-21 | Dr.Reddy's Laboratories,Inc. | $40,509 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Buprenorphine and Naloxone Drug, Psychiatry/Psychology | 2020 | |
| 2020-07-17 | Roche Products Limited | $151,293 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-07-17 | Gen-Probe, Inc. | $1,318 | Research payment | Cash or cash equivalent | Aptima Device, Diagnostics | Protocol Development Phase: Establishing surveillance for Mycoplasma genitalium and | 2020 |
| 2020-07-15 | Exelixis Inc. | $48,562 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-07-15 | Exelixis Inc. | $2,420 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-07-14 | Hikma Pharmaceuticals USA | $98,395 | Consulting Fee | Cash or cash equivalent | MORPHINE SULFATE Drug, Psychiatry/Psychology | 2020 | |
| 2020-07-13 | UPJOHN US 1 LLC | $50,000 | Research payment | Cash or cash equivalent | RADARS WILL COLLECT AND ANALYZE REAL WORLD PREGABALIN AND GABAPENTIN AND WILL PREPARE REPORT OF THEIR ANALYSES | 2020 | |
| 2020-07-12 | Indivior Inc. | $46,408 | Research payment | Cash or cash equivalent | Annual RADARS System Subscription/Lit Review | 2020 | |
| 2020-07-10 | Indivior Inc. | $54,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2020 | |
| 2020-07-08 | Roche Products Limited | $14,881 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-07-06 | Stryker Corporation | $93 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-06 | Stryker Corporation | $21 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-06 | Stryker Corporation | $5 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-01 | Purdue Pharma L.P. | $208,333 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-07-01 | Roche Products Limited | $147,981 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-07-01 | Purdue Pharma L.P. | $3,850 | Consulting Fee | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2020 | |
| 2020-07-01 | Emergent BioSolutions Inc. | $2,755 | Research payment | Cash or cash equivalent | Phase 2: A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating Safety, Pharmacokinetics and Clini | 2020 | |
| 2020-06-25 | Mallinckrodt LLC | $90,084 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-06-25 | Rhodes Pharmaceuticals L.P. | $25,511 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-06-25 | Mylan Specialty L.P. | $4,298 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-06-25 | Hikma Pharmaceuticals USA | $4,111 | Consulting Fee | Cash or cash equivalent | Morphine Sulfate ER tablets Drug, Psychiatry/Psychology | 2020 | |
| 2020-06-25 | Purdue Pharma L.P. | $3,939 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-06-25 | UPSHER-SMITH LABORATORIES LLC | $467 | Consulting Fee | Cash or cash equivalent | MORPHINE SULFATE EXTENDED RELEASE CAPSULES USP CII Drug, NEUROLOGY | 2020 | |
| 2020-06-22 | ZOLL Medical Corporation | $350 | Consulting Fee | Cash or cash equivalent | Device, DEFIBRILLATOR | 2020 | |
| 2020-06-19 | Siemens Medical Solutions USA, Inc. | $39,354 | Grant | In-kind items and services | 2020 | ||
| 2020-06-17 | Exelixis Inc. | $2,420 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-06-16 | Hikma Pharmaceuticals USA | $83,852 | Consulting Fee | Cash or cash equivalent | MORPHINE SULFATE Drug, Psychiatry/Psychology | 2020 | |
| 2020-06-16 | PENTAX of America, Inc. | $1,576 | Gift | In-kind items and services | Device, Gastroenterology | 2020 | |
| 2020-06-15 | Janssen Scientific Affairs, LLC | $302,400 | Research payment | Cash or cash equivalent | 2020 | ||
| 2020-06-15 | Hikma Pharmaceuticals USA | $55,443 | Consulting Fee | Cash or cash equivalent | Buprenorphine Drug, Endocrinology | 2020 | |
| 2020-06-13 | Indivior Inc. | $46,408 | Research payment | Cash or cash equivalent | Annual RADARS System Subscription/Lit Review | 2020 | |
| 2020-06-13 | Indivior Inc. | $3,375 | Research payment | Cash or cash equivalent | Annual RADARS System Subscription/Lit Review | 2020 | |
| 2020-06-12 | Purdue Pharma L.P. | $8,118 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-06-11 | UCB, Inc. | $32,500 | Research payment | Cash or cash equivalent | Implementation of Health Literacy Universal Precautions Toolkit for Rheumatology Quick Start impact on patient satisfact | 2020 | |
| 2020-06-10 | Exelixis Inc. | $49,063 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-06-04 | SANOFI PASTEUR INC. | $71,070 | Research payment | Cash or cash equivalent | STA00011 Stamaril Yellow Fever | 2020 | |
| 2020-06-01 | Roche Products Limited | $77,142 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-06-01 | Roche Products Limited | $10,200 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-05-29 | Purdue Pharma L.P. | $208,333 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-05-29 | Purdue Pharma L.P. | $52,200 | Consulting Fee | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2020 | |
| 2020-05-27 | Zimmer Biomet Holdings, Inc. | $3,500 | Research payment | Cash or cash equivalent | Continuum Device, Hips | CMU2010-02H, Continuum MoP PMCF | 2020 |
| 2020-05-27 | Roche Products Limited | $2,500 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-05-26 | Hikma Pharmaceuticals USA | $39,572 | Consulting Fee | Cash or cash equivalent | MORPHINE SULFATE Drug, Psychiatry/Psychology | 2020 | |
| 2020-05-20 | Purdue Pharma L.P. | $7,993 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-05-20 | Amgen Inc. | $5,094 | Research payment | Cash or cash equivalent | GALACTIC - HF | 2020 | |
| 2020-05-20 | Purdue Pharma L.P. | $2,502 | Consulting Fee | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2020 | |
| 2020-05-15 | Indivior Inc. | $3,000 | Research payment | Cash or cash equivalent | RADARS System DMI | 2020 | |
| 2020-05-14 | Novartis Pharmaceuticals Corporation | $245 | Research payment | Cash or cash equivalent | ARZERRA Drug, NEUROSCIENCE | A PHASE III OPEN LABEL RANDOMIZED MULTICENTER TRIAL OF OFATUMUMAB ADDED TO CHLORAMBUCIL VS CHLORAMBUCIL MONOTHERAPY IN P | 2020 |
| 2020-05-13 | Exelixis Inc. | $49,177 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-05-13 | Exelixis Inc. | $2,420 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-05-11 | Indivior Inc. | $46,408 | Research payment | Cash or cash equivalent | Annual RADARS System Subscription/Lit Review | 2020 | |
| 2020-05-11 | BONE SUPPORT AB | $1,238 | Research payment | Cash or cash equivalent | CERAMENT G Device, Bone void and fracture | A Prospective, Randomized Multicenter Controlled Trial of CERAMENT G as Part of Surgical Repair of Open Diaphyseal Tibia | 2020 |
| 2020-05-05 | ConvaTec Inc. | $466 | Charitable Contribution | Cash or cash equivalent | DuoDerm Device, WOUND THERAPEUTICS | 2020 | |
| 2020-05-01 | Stryker Corporation | $345 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-05-01 | Stryker Corporation | $111 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-05-01 | Stryker Corporation | $17 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-04-29 | Purdue Pharma L.P. | $208,333 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-04-22 | Purdue Pharma L.P. | $8,478 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-04-15 | Exelixis Inc. | $49,981 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-04-15 | Exelixis Inc. | $2,420 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-04-13 | UPJOHN US 1 LLC | $50,000 | Research payment | Cash or cash equivalent | RADARS WILL COLLECT AND ANALYZE REAL WORLD PREGABALIN AND GABAPENTIN AND WILL PREPARE REPORT OF THEIR ANALYSES | 2020 | |
| 2020-04-13 | PFIZER INC. | $7,500 | Research payment | Cash or cash equivalent | RADARS SYSTEM SUBSCRIPTION MORPHABOND | 2020 | |
| 2020-04-12 | Indivior Inc. | $56,250 | Research payment | Cash or cash equivalent | RADARS System DMI | 2020 | |
| 2020-04-08 | Emergent BioSolutions Inc. | $18,395 | Research payment | Cash or cash equivalent | Phase 2: A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating Safety, Pharmacokinetics and Clini | 2020 | |
| 2020-04-07 | Hikma Pharmaceuticals USA | $49,440 | Consulting Fee | Cash or cash equivalent | MORPHINE SULFATE Drug, Psychiatry/Psychology | 2020 | |
| 2020-04-03 | Indivior Inc. | $54,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2020 | |
| 2020-04-02 | Hikma Pharmaceuticals USA | $24,937 | Consulting Fee | Cash or cash equivalent | MORPHINE SULFATE Drug, Psychiatry/Psychology | 2020 | |
| 2020-04-02 | Zimmer Biomet Holdings, Inc. | $3,038 | Research payment | Cash or cash equivalent | Continuum Device, Hips | CMU2010-02H, Continuum MoP PMCF | 2020 |
| 2020-04-01 | Purdue Pharma L.P. | $416,666 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-03-30 | Gilead Sciences, Inc. | $19,200 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2020 | |
| 2020-03-28 | Indivior Inc. | $92,816 | Research payment | Cash or cash equivalent | Annual RADARS System Subscription/Lit Review | 2020 | |
| 2020-03-27 | Purdue Pharma L.P. | $9,397 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-03-26 | BTG International Inc. | $47,170 | Research payment | Cash or cash equivalent | CROFAB Drug, ANTI-VENOM | CROFAB | 2020 |
| 2020-03-26 | BTG International Inc. | $1,264 | Research payment | Cash or cash equivalent | CROFAB Drug, ANTI-VENOM | CROFAB | 2020 |
| 2020-03-25 | Exelixis Inc. | $48,511 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-03-25 | Exelixis Inc. | $2,420 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabozantinib Drug, Oncology | 2020 | |
| 2020-03-24 | Hikma Pharmaceuticals USA | $15,164 | Consulting Fee | Cash or cash equivalent | MORPHINE SULFATE Drug, Psychiatry/Psychology | 2020 | |
| 2020-03-23 | ZOLL Medical Corporation | $350 | Consulting Fee | Cash or cash equivalent | Device, DEFIBRILLATOR | 2020 | |
| 2020-03-13 | Indivior Inc. | $78,850 | Research payment | Cash or cash equivalent | RADARS System DMI | 2020 | |
| 2020-03-13 | Purdue Pharma L.P. | $385 | Consulting Fee | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2020 |
The latest 200 records of 237.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Denver, CO, county Denver County, CO, state Colorado; placed by its city name.
| Measure | Place (city or town) Denver, CO | County Denver County, CO | State Colorado |
|---|---|---|---|
| Population B01003 | 718,877 | 718,877 | 5,862,189 |
| Population, 2020 census P1 | 715,522 | 715,522 | 5,773,714 |
| Median age B01002 | 35.3 | 35.3 | 37.7 |
| Under 18 B01001 | 18.0% | 18.0% | 21.0% |
| 65 and over B01001 | 12.5% | 12.5% | 15.6% |
| Households B11001 | 335,428 | 335,428 | 2,374,218 |
| Foreign born B05002 | 14.5% | 14.5% | 9.8% |
| Median household income B19013 | $94,718 | $94,718 | $95,470 |
| Median family income B19113 | $124,743 | $124,743 | $119,139 |
| Per capita income B19301 | $64,163 | $64,163 | $52,636 |
| Poverty rate B17001 | 11.2% | 11.2% | 9.4% |
| Unemployment rate B23025 | 4.9% | 4.9% | 4.6% |
| Civilian labor force B23025 | 447,681 | 447,681 | 3,235,476 |
| Mean commute (minutes) B08013 | 24.9 | 24.9 | 25.2 |
| Bachelor's degree or higher B15003 | 56.5% | 56.5% | 45.7% |
| Housing units B25001 | 359,581 | 359,581 | 2,589,053 |
| Owner-occupied B25003 | 48.8% | 48.8% | 66.2% |
| Renters B25003 | 51.2% | 51.2% | 33.8% |
| Median home value B25077 | $616,000 | $616,000 | $539,400 |
| Median gross rent B25064 | $1,831 | $1,831 | $1,761 |
| White, not Hispanic B03002 | 54.0% | 54.0% | 64.8% |
| Black B03002 | 8.6% | 8.6% | 3.8% |
| Hispanic or Latino B03002 | 28.0% | 28.0% | 22.5% |
| Asian B03002 | 3.6% | 3.6% | 3.2% |
| American Indian and Alaska Native B03002 | 0.3% | 0.3% | 0.4% |
Economy now FRED unemployment 4.1% in Sep 2026 (3.8% a year earlier); per capita personal income $86,342 in 2025, up 34% in five years (+7.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Denver, CO.
Comments